Medicina de Emergências
OMS recomenda dois novos medicamentos (baricitinibe e sotrovimabe) para tratar COVID-19.
20 Jan, 2022 | 20:20hComunicado de imprensa: WHO recommends two new drugs to treat COVID-19 – World Health Organization
Infográfico com recomendações atualizadas: A living WHO guideline on drugs for covid-19 – The BMJ
Comentários:
Comentário no Twitter (fio – clique para saber mais)
WHO has also conditionally recommended the use of sotrovimab for treating mild or moderate #COVID19 in patients who are at high risk of hospitalization: patients who are older, immunocompromised, with underlying conditions & those unvaccinated https://t.co/UAc21Wgxbl https://t.co/Z39mSKrOv5
— World Health Organization (WHO) (@WHO) January 14, 2022
Ponto de vista | Tratamentos para COVID-19 para pacientes não internados.
20 Jan, 2022 | 20:11hCOVID-19 Therapeutics for Nonhospitalized Patients – JAMA
Editorial: Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management – JAMA
Diretriz multidisciplinar | Tratamento da nefrolitíase na gestação.
20 Jan, 2022 | 19:59h
Comentário do autor no Twitter
https://t.co/bFtOYFgBmr Started as an assigned resident presentation. Turned into a set of multi-d guidelines implemented at the university level. Now published for all to reference! Thank you all authors for input & guidance @peepeeDoctor @willrobe1 @amy_krambeck @sapanambani
— Matthew Lee (@MSLee_MD) December 23, 2021
Estudo randomizado | Em pacientes submetidos a entubação endotraqueal, a sobrevida de 7 dias foi significativamente menor com etomidato vs. cetamina (77,3% vs. 85,1%), mas as taxas de sobrevida em 28 dias não foram significativamente diferentes (etomidato 64,1% vs. cetamina 66,8%, p = 0,294).
20 Jan, 2022 | 19:44h
Comentário no Twitter
Etomidate vs ketamine for emergency endotracheal intubation, RCT
💉801 critically ill pts assigned to receive etomidate (0.2–0.3 mg/kg) or ketamine (1–2 mg/kg)
💉day 7 survival significantly lower with etomidate
💉no significantly different day 28 survivalhttps://t.co/CkxufORC8A pic.twitter.com/xQ4AtCifc7— Intensive Care Medicine (@yourICM) December 17, 2021
Fluvoxamina para Covid-19: o que médicos e farmacêuticos precisam saber.
17 Jan, 2022 | 13:14hFluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario
Conteúdos relacionados:
Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.
Comentário no Twitter
Thinking of prescribing fluvoxamine for covid 19? Ontario has a nice infographichttps://t.co/MKT8PqlJpM
— Todd Lee (@DrToddLee) January 12, 2022
Diretriz de posicionamento AAN | Questões de consentimento no tratamento do AVC isquêmico agudo.
17 Jan, 2022 | 13:07hConsent Issues in the Management of Acute Ischemic Stroke: AAN Position Statement – Neurology
Comunicado de imprensa: Who gives consent for treatment when a person with stroke cannot? – American Academy of Neurology
Revisão sistemática | Limiares restritivos de transfusão podem reduzir as transfusões de forma segura em até 41% em uma ampla variedade de contextos clínicos.
17 Jan, 2022 | 13:01hTransfusion thresholds for guiding red blood cell transfusion – Cochrane Library
Conteúdos relacionados:
Research: Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery
Transfusion Requirements After Cardiac Surgery: The TRACS Randomized Controlled Trial – JAMA
Comentário no Twitter
Less can be more: updated Cochrane review strengthens conclusions on safety of restrictive transfusion thresholds https://t.co/uKkvX5UJrS @EUBloodAlliance @WHO @AABB @NIHRresearch @CochraneLibrary @NICEComms @NHSBT @RutgersU @LSHTM @RDMOxford #transfusionmedicine pic.twitter.com/2QXQNqzvPK
— Cochrane Injuries (@cochraneINJ) December 22, 2021
Estudo randomizado | Rendesivir iniciado precocemente em pacientes ambulatoriais pode prevenir a progressão para Covid-19 grave.
13 Jan, 2022 | 21:18hEditorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right?
Comentário: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress
Comentário no Twitter
Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. #COVID19 #IDTwitter https://t.co/YFflw5nBxB pic.twitter.com/4NCD9AcnYH
— NEJM (@NEJM) December 22, 2021
Outro estudo mostrou que as terapias com anticorpos monoclonais neutralizantes não são eficazes quando administradas depois de o paciente já estar internado.
13 Jan, 2022 | 21:13hComentário convidado: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
Estudo de coorte | Fatores associados ao paciente preditivos de apendicectomia dentro de 30 dias após o início da antibioticoterapia para apendicite – A presença de um apendicólito foi associada com cerca de 2 vezes mais risco de apendicectomia em 30 dias.
13 Jan, 2022 | 21:06hPatient Factors Associated With Appendectomy Within 30 Days of Initiating Antibiotic Treatment for Appendicitis – JAMA Surgery (gratuito por tempo limitado)
Comentário convidado: Appendicoliths, Antibiotic Treatment Failure, and Appendectomy—Is the Glass Half Full or Half Empty? – JAMA Surgery